Equities research analysts forecast that Insys Therapeutics (NASDAQ:INSY) will report earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Insys Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.12) and the lowest estimate coming in at ($0.17). Insys Therapeutics reported earnings per share of $0.03 during the same quarter last year, which suggests a negative year-over-year growth rate of 600%. The company is expected to announce its next quarterly earnings report on Thursday, August 2nd.
On average, analysts expect that Insys Therapeutics will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.64) to ($0.58). For the next year, analysts anticipate that the company will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.33) to ($0.20). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Insys Therapeutics.
Insys Therapeutics (NASDAQ:INSY) last announced its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.01). The firm had revenue of $23.90 million for the quarter, compared to the consensus estimate of $25.82 million. Insys Therapeutics had a negative return on equity of 43.27% and a negative net margin of 188.01%. Insys Therapeutics’s revenue for the quarter was down 33.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.09) EPS.
INSY has been the topic of a number of recent research reports. Zacks Investment Research upgraded Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 31st. ValuEngine lowered Insys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, March 23rd. Oppenheimer restated a “hold” rating on shares of Insys Therapeutics in a research note on Wednesday, May 9th. Finally, Cann restated an “average” rating on shares of Insys Therapeutics in a research note on Friday, March 2nd. Three analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $9.38.
Shares of NASDAQ INSY opened at $6.87 on Monday. The company has a market cap of $527.00 million, a PE ratio of -14.02 and a beta of 1.09. Insys Therapeutics has a 1-year low of $4.10 and a 1-year high of $14.00.
In other Insys Therapeutics news, Director Brian Tambi sold 166,504 shares of the firm’s stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $6.41, for a total transaction of $1,067,290.64. Following the transaction, the director now owns 4,000 shares in the company, valued at approximately $25,640. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 67.90% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the business. ETF Managers Group LLC boosted its holdings in shares of Insys Therapeutics by 130.2% in the 1st quarter. ETF Managers Group LLC now owns 649,898 shares of the specialty pharmaceutical company’s stock valued at $3,873,000 after purchasing an additional 367,630 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Insys Therapeutics by 116.1% in the 4th quarter. Deutsche Bank AG now owns 53,827 shares of the specialty pharmaceutical company’s stock valued at $515,000 after purchasing an additional 28,923 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Insys Therapeutics by 303.5% in the 1st quarter. JPMorgan Chase & Co. now owns 25,624 shares of the specialty pharmaceutical company’s stock valued at $155,000 after purchasing an additional 19,273 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Insys Therapeutics by 37.3% in the 4th quarter. Wells Fargo & Company MN now owns 57,020 shares of the specialty pharmaceutical company’s stock valued at $549,000 after purchasing an additional 15,504 shares in the last quarter. Finally, Raymond James & Associates boosted its holdings in shares of Insys Therapeutics by 93.5% in the 4th quarter. Raymond James & Associates now owns 31,008 shares of the specialty pharmaceutical company’s stock valued at $298,000 after purchasing an additional 14,982 shares in the last quarter. Hedge funds and other institutional investors own 17.78% of the company’s stock.
About Insys Therapeutics
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.